Phathom Pharmaceuticals goes public
Menlo Park, California-based Phathom Pharmaceuticals, a biopharmaceutical company focused on treating gastrointestinal diseases, has raised about $181.7 million for its IPO after pricing its over 9.5 million shares at $19 per share. The stock began trading October 25, 2019 on the NASDAQ under the ticker symbol "PHAT." Goldman Sachs, Jefferies and Evercore ISI are the lead underwriters. Phathom's pre-IPO backers include Frazier Healthcare Partners, Medicxi, RA Capital Management, Abingworth, BVF Partners LP, Greenspring Associates, Richard King Mellon Foundation and Sahsen.
25 October 2019•2 mins read
